Emergent Travel Health Inc.
Doing business as Emergent Travel Health Inc.
- UEI
- CXEUFMM1FXY8
- CAGE
- 4VVA0
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- emergentbiosolutions.com
- Founded
- 1998
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Extended stability program testing of two adenoviral HIV vaccine candidates | National Institute of Allergy and Infectious Diseases | $697,945 | |
| Paxvax vaccines - polio | Headquarters Division | $0 | |
| PAC VAX vacine | Headquarters Division | $14,183 | |
| Immunizations required for FBI workforce involved in operational deployments CONUS and OCONUS. | Headquarters Division | $13,916 | |
| Sbir PH III 17-0001A topic A14-045 modernized production adenovirus vaccine (mpav), DPA title III, pre-objective 1 | Medical Command | $652,166 |
About Emergent Travel Health Inc.
Emergent Travel Health Inc. is a multinational specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases, oncology and autoimmune disorders. It has provided a range of goods and services to the federal government including vaccine stability testing, vaccine development, and vaccine procurement.
Through prime federal contracts, Emergent Travel Health Inc. has provided extended stability program testing of two adenoviral HIV vaccine candidates for the National Institutes of Health's National Institute of Allergy and Infectious Diseases. It has also provided polio vaccines to the Department of Justice's Federal Bureau of Investigation Headquarters Division. The contracts were firm fixed price, blanket purchase agreement calls, and purchase orders awarded on a sole source basis with no set aside designations.
As a prime federal grant recipient, Emergent Travel Health Inc. received a $431,088 Project Grant from the Defense Health Agency to evaluate the safety and efficacy of a virus-like particle vaccine candidate for the prevention of Chikungunya virus disease. The work is being conducted at the company's facility in Redwood City, California.
Emergent Travel Health Inc. holds a federal supply schedule contract through the Department of Veterans Affairs to provide drugs, pharmaceuticals and hematology related products. The multiple award contract allows federal agencies to purchase these goods through August 2021.
Quick answers
What is Emergent Travel Health Inc.'s UEI?
Emergent Travel Health Inc.'s Unique Entity ID (UEI) in SAM.gov is CXEUFMM1FXY8.
What is Emergent Travel Health Inc.'s CAGE code?
Emergent Travel Health Inc.'s CAGE code is 4VVA0.
What is Emergent Travel Health Inc.'s primary NAICS code?
Emergent Travel Health Inc.'s primary NAICS code is 325414 (Biological Product (except Diagnostic) Manufacturing).
Is Emergent Travel Health Inc. registered in SAM.gov?
Emergent Travel Health Inc.'s SAM.gov registration expired on August 29, 2025.
What is Emergent Travel Health Inc.'s most recent federal award?
Emergent Travel Health Inc.'s most recent federal contract award is Extended stability program testing of two adenoviral HIV vaccine candidates (75N93022P01224), from National Institute of Allergy and Infectious Diseases, on September 16, 2022.
On GovTribe
See Emergent Travel Health Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors